Iowa Lottery Action, February 6-9, 2006, Vol. 13, no. 3

Iowa Lottery newsletter for retailers

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.

Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of a central pathology review, we addressed the question if patients with GBM displaying distinct morphologic features respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were systematically recorded for 360 cases with particular focus on the presence of an oligodendroglioma-like component and respective correlations with outcome and relevant molecular markers. GBM with an oligodendroglioma-like component (GBM-O) represented 15% of all confirmed GBM (52/339) and was not associated with a more favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, significantly enriched for IDH1 mutations (19 vs. 3%, p = 0.003) and EGFR amplifications (71 vs. 48%, p = 0.04) compared with other GBM, while co-deletion of 1p/19q was found in only one case and the MGMT methylation frequency was alike (47 vs. 46%). Expression profiles classified most of the GBM-O into two subtypes, 36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-palisading necrosis (PPN) was associated with benefit from chemotherapy (p = 0.0002), while no such effect was present in the absence of PPN (p = 0.86). In the adjusted interaction model including clinical prognostic factors and MGMT status, PPN was borderline nonsignificant (p = 0.063). Taken together, recognition of an oligodendroglioma-like component in an otherwise classic GBM identifies a pathogenetically mixed group without prognostic significance. However, the presence of PPN may indicate biological features of clinical relevance for further improvement of therapy.

6,5 · 10-9

Segons l’Institut Nacional d’Estadística, cada espanyol es gasta una mitjana de208 euros a l’any en loteries. L’objectiu principal és guanyar el primer premi, peròsaben realment quina probabilitat tenen d’aconseguir-ho?L’objectiu principal del treball és estudiar el funcionament, les probabilitats i lespreferències dels individus pel que fa a les loteries. Donat que és un sector molt ampli icomplex hem decidit centrar-nos en aquelles que tenen una major acceptació.Les loteries no només son un tema d’interès general sinó que ens han permès aprofundiren els coneixements estadístics adquirits a les assignatures de Probabilitat, Estadística iDecisió i Competència Estratègica.L’anàlisi del treball es centrarà en el càlcul de les probabilitats. Els ingressos de l’Estatprovinents dels impostos sobre la comercialització i sobre els beneficis generats per laloteria també es veuran reflectits en l’estudi. A més analitzarem les preferències de lapoblació a l’hora de jugar a la loteria mitjançant la realització d’enquestes. Després decomparar els resultats obtinguts en les enquestes amb les probabilitats calculadesinicialment, realitzarem una simulació que ens permetrà aprofundir més en el tema.El càlcul de les probabilitats de guanyar en cada joc no estan reflectits en cap documentoficial. Aquest fet resulta paradoxal ja que els càlculs no tenen una gran complicació,aleshores, per què no son públics? Segurament perquè el coneixement d’aquestes dadesfaria que la gent deixes de jugar, amb el que els extensos ingressos procedents de lacomercialització de loteries, disminuiria considerablement.

Iowa Department of Elder Affairs Legislative Update, February 11, 2005, Vol. 1, no. 6

Iowa Department of Elder Affairs provides a brief summation of a Departmental program or other important Departmental information in each Legislative Update. The Legislative Update is produced for informational and educational purposes only.

Iowa Department of Elder Affairs Legislative Update with Attachments, February 17, 2006, Vol. 2, no. 6

Iowa Department of Elder Affairs provides a brief summation of a Departmental program or other important Departmental information in each Legislative Update. The Legislative Update is produced for informational and educational purposes only.

A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon-alpha-2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C (PRACTICE).

BACKGROUND AND STUDY AIMS: This was an observational, non-interventional, multicenter, phase IV study, in patients with genotype 1/4/5/6 chronic hepatitis C (CHC). The primary objectives were to evaluate SVR in patients with no or minimal fibrosis (METAVIR F0-F1) versus well established fibrosis (F2-F4), and to estimate response on Weeks 12, 24 and 48 on treatment in previously untreated patients with genotypes 1/4/5/6 CHC. PATIENTS AND METHODS: 538 patients treated with pegylated interferon alfa 2b 1.5 mcg/kg in combination with ribavirin 800-1200 mg/day were enrolled in 55 sites in Belgium and Luxembourg, 505 being considered for the analysis. 40% of the patients were female and 60% male, the average age was 47.5 years, 10.5% were 65 or older. RESULTS: SVR was observed in 35% of the patients, EVR in 68%, of which pEVR in 33% and cEVR in 35%. SVR was observed in 43% of the low fibrosis group (F0, F1) and 30% of the high fibrosis group (F2, F3, F4) (p = 0.005). SVR rates were 34% for genotype 1, 37% for genotype 4, and 47% for genotype 5 (NS). Multivariate analysis showed that EVR and baseline METAVIR score are independent prognostic factors for SVR. CONCLUSIONS: This trial confirms that fibrosis stage and early viral response are the most important key-factors to predict sustained response, suggesting that the earlier patients are treated, the better the outcome. Non-invasive techniques enable us to closely monitor progression of fibrosis, allowing a better selection of patients for antiviral treatment in the DAA-era.

Iowa Lottery Action, March 20-April 2, Vol. 13, no. 6

Iowa Lottery newsletter for retailers

Iowa Lottery Action, March 6-19, 2006, vol. 13, no. 5

Iowa Lottery newsletter for Lottery retailers.